REG-Bioventix Plc: Posting of Annual Report and Notice of AGM

BioventixAnnouncement

11/11/2021 14:35

Bioventix plc
(“Bioventix” or the “Company”)

Posting of Annual Report and Notice of AGM

Bioventix plc (BVXP), a UK company specialising in the development and
commercial supply of high-affinity monoclonal antibodies for applications in
clinical diagnostics, confirms that its Annual Report and Accounts for the
year ended 30 June 2021 and the Notice of Annual General Meeting (“AGM”)
has been posted to shareholders.

These documents are available on the Company's website at www.bioventix.com.

The AGM will be held at Farnham Castle, Farnham, Surrey, GU9 0AG at 2.00 p.m.
on 9 December 2021.

The Board continues to monitor the situation surrounding COVID-19 and the
advice from the Government on public gatherings. If the Government’s
guidance changes at any point prior to the AGM, such that shareholders are
unable to attend in person, the Company will update shareholders through an
announcement to the London Stock Exchange and on the Company’s website. In
light of this uncertainty, the Board strongly encourages shareholders to
submit a proxy vote in advance of the AGM and to appoint the Chairman of the
AGM as their proxy, rather than a named person who, if circumstances change,
may not the able to attend the AGM.

For further information please contact:

 Bioventix plc Peter Harrison Bruce Hiscock     Chief Executive Officer Chief Financial Officer  Tel: 01252 728 001  
                                                                                                                     
 finnCap Ltd Geoff Nash/Simon Hicks Alice Lane  Corporate Finance ECM                            Tel: 020 7220 0500  

About Bioventix plc:

Bioventix (www.bioventix.com) specialises in the development and commercial
supply of high-affinity monoclonal antibodies with a primary focus on their
application in clinical diagnostics, such as in automated immunoassays used in
blood testing. The antibodies created at Bioventix are generated in sheep and
are of particular benefit where the target is present at low concentration and
where conventional monoclonal or polyclonal antibodies have failed to produce
a suitable reagent. Bioventix currently offers a portfolio of antibodies to
customers for both commercial use and R&D purposes, for the diagnosis or
monitoring of a broad range of conditions, including heart disease, cancer,
fertility, thyroid function and drug abuse. Bioventix currently supplies
antibody products and services to the majority of multinational clinical
diagnostics companies. Bioventix is based in Farnham, UK and its shares are
traded on AIM under the symbol BVXP.



Copyright (c) 2021 PR Newswire Association,LLC. All Rights Reserved